Evidence mapPaperPMID 41724967Full record

ArticleCardiovascular diabetology2026

Triglyceride glucose index-a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging.

Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Peishu Li, Yifei Feng, Jiayuan Zhang, Bangde Xiang

Abstract readComparative Study
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guodong Yang *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Wenli He *Department of Cardiology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Xin Qiu *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Shuang Shen *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Peishu LiDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Yifei FengOncology School, Guangxi Medical University, Nanning, 530021, China.
Jiayuan ZhangOncology School, Guangxi Medical University, Nanning, 530021, China.
Bangde XiangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China. xiangbangde@gxmu.edu.cn.

Funding

Development and application of medical and health appropriate technology in Guangxi S2019039High-level innovation team and outstanding scholar program in Guangxi Colleges and Universities, "139" projects for training high-level medical science talents from Guangxi G201903001National Major Special Science and Technology Project 2017ZX10203207Self-funded Scientific Research Project of the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region Z-A20240412The Key Laboratory of Early Prevention and Treatment for Regional High-Frequency Tumor, Ministry of Education/Guangxi, Independent Research Project GKE2017-ZZ02, GKE2018-KF02, GKE2019-ZZ07The Key Research and Development Project of Guangxi AB20297009, AA18221001, AB18050020the National Natural Science Foundation of China 82260573Youth Science Foundation of Guangxi Medical University GXMUYSF202321
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is burdened by significant all-cause and cardiovascular mortality, yet simple and effective predictive indices for long-term outcomes are currently lacking. In this study, we investigated the prognostic value of the triglyceride glucose-a body shape index (TyG-ABSI), a novel composite of insulin resistance and visceral adiposity, for mortality in MASLD.

methodsThis prospective cohort study included 7515 adults with MASLD from the National Health and Nutrition Examination Survey (NHANES, 1999-2018). MASLD was defined as a Fatty Liver Index ≥ 60 accompanied by at least one cardiometabolic risk factors. The primary outcomes were all-cause mortality (ACM) and cardiovascular mortality (CVM). Kaplan-Meier survival curves, multivariable Cox regression, restricted cubic splines (RCS), and receiver operating characteristic (ROC) analyses were employed to evaluate the predictive value of TyG-ABSI. Additionally, subgroup, sensitivity, and mediation analyses were conducted to verify robustness and explore underlying mechanisms.

resultsDuring a median follow-up of 138 months, 1368 all-cause and 376 cardiovascular deaths were recorded. TyG-ABSI demonstrated improved predictive accuracy compared to TyG, TyG-BMI, TyG-WC, and TyG-WHtR, as evidenced by higher AUC values and significant Net Reclassification Improvement(NRI). In fully adjusted models, participants in the highest TyG-ABSI quartile faced significantly elevated risks of ACM (HR 1.49, 95% CI 1.03-2.14) and CVM (HR 2.32, 95% CI 1.02-5.30) relative to the lowest quartile. RCS analysis indicated a linear dose-response relationship, and the associations remained robust across subgroup and sensitivity analyses. Mediation analysis revealed that accelerated biological aging significantly mediated mortality risks, with KDM and HD explaining 24.75% and 32.15% of ACM, and 34.89% and 46.53% of CVM, respectively.

conclusionsTyG-ABSI serves as a robust, independent predictor of mortality in patients with MASLD, outperforming traditional TyG-related metrics. The association is significantly associated with the pathway of accelerated biological aging, highlighting the utility of TyG-ABSI for enhanced risk stratification in clinical practice.

Indexed as

AdiposityAgingBlood GlucoseCardiovascular DiseasesFatty LiverInsulin ResistanceNon-alcoholic Fatty Liver DiseaseTriglyceridesAdultAgedAge FactorsBiomarkersCause of DeathFemaleHumansIntra-Abdominal FatBiomarkersBlood GlucoseTriglyceridesA body shape indexBiological ageMetabolic dysfunction-associated steatotic liver disease (MASLD)MortalityTriglyceride-glucose index

Identifiers

PMID41724967
PMCPMC13032404

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.